CARGO Therapeutics is a clinical-stage biotechnology company engaged in curative cell therapies for cancer patients. Co.'s programs, platform technologies, and manufacturing are designed for chimeric antigen receptor (CAR) T-cell therapies. Co.'s lead program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by CD22, a tumor antigen that is vast majority of B-cell malignancies. The CRGX average annual return since 2023 is shown above.
The Average Annual Return on the CRGX average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CRGX average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CRGX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|